Skip to main
QNCX
QNCX logo

QNCX Stock Forecast & Price Target

QNCX Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Quince Therapeutics Inc. has established a strong intellectual property position through multiple patent allowances, enhancing market exclusivity and providing a competitive edge for its lead asset, EryDex, indicating potential for long-term commercial success. The company’s compelling safety data supporting EryDex’s efficacy in treating Ataxia-Telangiectasia (A-T) reinforces its transformative potential in patient care, with the possibility of regulatory submissions set for 2026 serving as a significant milestone. With a robust cash position of $47.8 million as of Q3 2024, Quince is well-positioned to advance its clinical programs and achieve key regulatory objectives in the upcoming years.

Bears say

Quince Therapeutics is at a preclinical stage with a drug pipeline focused on rare diseases, which may pose significant risks related to the uncertain timelines and regulatory hurdles associated with drug development. The lack of revenue generation due to its early-stage status raises concerns about the company's financial sustainability, especially given the high costs involved in bringing therapeutic products to market. Additionally, the potential for limited market acceptance and competition within the biopharmaceutical sector further complicates the outlook for Quince Therapeutics' stock performance.

QNCX has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quince Therapeutics Inc (QNCX) Forecast

Analysts have given QNCX a Strong Buy based on their latest research and market trends.

According to 6 analysts, QNCX has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quince Therapeutics Inc (QNCX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.